Despite multiple improvements in management, including molecular markers, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) targeted treatments as well as immune checkpoint inhibitors, that have resulted in improvement in lung cancer mortality, there remains a significant risk of metastases [3]. This evidence concerns the gene ALK and lung carcinoma.